Badr, Mohamed
Jöhrens, Korinna
Allgäuer, Michael
Boxberg, Melanie
Weichert, Wilko
Tinhofer, Ingeborg
Denkert, Carsten
Schirmacher, Peter
Stenzinger, Albrecht
Budczies, Jan http://orcid.org/0000-0002-6668-5327
Funding for this research was provided by:
German Cancer Consortium (None, None, None, None, None)
Article History
Received: 17 April 2019
Accepted: 10 August 2019
First Online: 23 August 2019
Compliance with ethical standards
:
: W. Weichert received consultant/advisory board as well as speaker’s honoraria from Roche, Merck Sharp & Dohme (MSD), Bristol-Myers Squibb (BMS), AstraZeneca, Pfizer, Merck, Lilly, Boehringer, Novartis and Takeda. He received research funding from Roche, MSD, BMS and Bruker. C. Denkert received consultant/advisory board honoraria from MSD, Amgen and Daiichi Sankyo as well as speaker’s honoraria from Teva, Novartis, Pfizer, Roche and Amgen. He has stock and other ownership interests concerning Sividon Diagnostics. P. Schirmacher received consultant/advisory board honoraria from Pfizer, Roche, Novartis and AstraZeneca as well as speaker’s honoraria and research funding from Roche, AstraZeneca and Novartis. A. Stenzinger received consultant/advisory board honoraria from AstraZeneca, BMS, Novartis, Thermo Fisher Scientific and Illumina as well as speaker’s honoraria from BMS, MSD, Roche, Illumina, AstraZeneca, Novartis and Thermo Fisher as well as research funding from Chugai and BMS. The authors declare that there are no other conflicts of interest.
: The TCGA HNSCC data are freely available without restrictions for use in publications.